A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs NCI-4650 (Primary)
Indications Adenocarcinoma; Carcinoma; Colon cancer; Gastric cancer; Gastrointestinal cancer; Malignant melanoma; Rectal cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

08 Nov 2019 Status changed from completed to discontinued.
06 Nov 2019 According to a Moderna Therapeutics media release, data from this study has been submitted for the publication.
26 Jun 2019 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com